(Q46957617)

26 December 2017

title

Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome (English)

1 reference

26 December 2017

1 reference

Yasushi Kojima

1

1 reference

26 December 2017

Hisashi Tsurumi

2

1 reference

26 December 2017

Naoe Goto

3

1 reference

26 December 2017

Masahito Shimizu

4

1 reference

26 December 2017

Senji Kasahara

5

1 reference

26 December 2017

Toshiki Yamada

6

1 reference

26 December 2017

Nobuhiro Kanemura

7

1 reference

26 December 2017

Takeshi Hara

8

1 reference

26 December 2017

Michio Sawada

9

1 reference

26 December 2017

Masanao Saio

10

1 reference

26 December 2017

Tetsuya Yamada

11

1 reference

26 December 2017

Takeshi Takahashi

12

1 reference

26 December 2017

Eiichi Tomita

13

1 reference

26 December 2017

Tsuyoshi Takami

14

1 reference

26 December 2017

Hisataka Moriwaki

15

1 reference

26 December 2017

publication date

23 February 2006

1 reference

26 December 2017

European Journal of Haematology

published in

1 reference

26 December 2017

volume

76

1 reference

26 December 2017

issue

6

1 reference

26 December 2017

page(s)

465-472

1 reference

26 December 2017

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00631.X

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00631.X

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00631.X

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00631.X

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00631.X

Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00631.X

Building an outcome predictor model for diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00631.X

Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00631.X

Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00631.X

CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00631.X

The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00631.X

Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00631.X

Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00631.X

The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00631.X

Autoimmune lymphoproliferative syndrome with somatic Fas mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00631.X

The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00631.X

Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00631.X

CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00631.X

Prognostic relevance of Fas (APO-1/CD95) ligand in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00631.X

Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2006.00631.X

10.1111/J.1600-0609.2006.00631.X

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

release_n6syqnh3jjfurcvbe5uf2w272q

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/n6syqnh3jjfurcvbe5uf2w272q

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

26 December 2017